Applied Genetic Technologies Corp.
(NASDAQ : AGTC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.13%105.021.1%$1269.72m
GILDGilead Sciences, Inc.
0.11%72.900.9%$642.29m
AMGNAmgen Inc.
0.17%170.251.1%$478.76m
REGNRegeneron Pharmaceuticals, Inc.
0.77%390.512.7%$361.84m
BIIBBiogen Inc.
-0.30%308.881.2%$348.76m
ALXNAlexion Pharmaceuticals, Inc.
0.80%108.461.9%$268.77m
VRTXVertex Pharmaceuticals Incorporated
-0.25%146.681.9%$232.15m
ALNYAlnylam Pharmaceuticals, Inc
0.91%133.5310.0%$194.91m
INCYIncyte Corporation
-0.29%98.712.5%$178.72m
NKTRNektar Therapeutics
-1.69%48.916.1%$173.60m
ILMNIllumina, Inc.
-0.15%215.033.5%$154.29m
JUNOJuno Therapeutics, Inc.
2.01%61.5413.5%$140.39m
AAgilent Technologies, Inc.
0.48%69.021.5%$132.29m
SRPTSarepta Therapeutics, Inc.
0.22%56.3416.8%$115.87m
BLUEBluebird Bio, Inc.
0.98%168.8417.2%$115.55m

Company Profile

Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.